Supplementary appendix
|
|
- Estella Wheeler
- 6 years ago
- Views:
Transcription
1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Churchyard GJ, Stevens WS, Mametja LD, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3: e
2 Web appendix Supplement to: Churchyard GJ, Stevens W, Lerole D, et al. Xpert MTB/RIF replacing sputum microscopy as the initial diagnostic test for tuberculosis: a cluster randomised trial embedded in South African roll out Selection of clinics We selected two primary care clinics served by each laboratory. Clinics were assessed for eligibility using data on the number of sputum specimens sent to the National Health Laboratory Service in Clinics were eligible for selection if the estimated number of diagnostic specimens in a three-month period (the planned recruitment period for the study) was greater than 200. For two laboratories, clinics with an estimated threemonth diagnostic specimen load of at least 150 were chosen as there was a paucity of clinics with a load of greater than 200. Xpert MTB/Rif implementation After initiation of testing with Xpert MTB/RIF at each laboratory, the National Priorities Programme of the National Health Laboratory Service monitored stock inventory, machine utilization rate, results (including error and invalid rates) and turn-around-time at each site, using remote connectivity. Periodic refresher training was held for laboratory staff, and directed interventions were conducted in response to high error or invalid rates from specific sites. A national stock-out of Xpert MTB/RIF cartridges occurred in May 2013 (due to a global stock-out), but through careful re-distribution of existing stock, and delaying commencement of enrolment into XTEND in province A, this did not affect the progress of the XTEND study. Data management At enrolment, a unique participant number was generated. Completed case report forms were submitted in an encrypted format via the cell phone network into a central repository database maintained by an independently contracted software company. These data were available on a password protected website for real-time review by investigators, statisticians and data managers. Weekly downloads via secure FTP server to the Aurum Institute database facilitated review of data, and data cleaning. Statistical analysis Primary outcome: mortality Mortality was measured as a risk over the six-month follow-up period (182 days) from enrolment. Participants whose vital status was not known at six months were assumed to be alive. A sensitivity analysis was conducted, excluding participants whose vital status was not known at six months. Secondary outcomes 1. Proportion with a positive (microscopy or Xpert MTB/RIF) index specimen: This analysis was restricted to participants with a positive or negative (microscopy or Xpert MTB/RIF) index specimen result. A scanty microscopy result was assumed to be positive, in accordance with National guidelines. 2. Proportion not started on tuberculosis treatment within 28 days of enrolment among those with positive index specimen This analysis was restricted to participants with a positive (microscopy or Xpert MTB/RIF) index specimen. A scanty microscopy result was assumed to be positive. The outcome was defined as not starting tuberculosis treatment within 28 days of enrolment. If a participant had died during the first 28 days from enrolment and not started on tuberculosis treatment prior to death they were included in the denominator and numerator. 1
3 3. Proportion starting tuberculosis treatment over a six-month period from enrolment. This analysis was based on all participants recruited into the cohort. Starting tuberculosis treatment was measured as a risk over the six-month follow-up period (182 days) from enrolment. Participants who started treatment on the same day as enrolment contributed to the numerator and denominator. Analysis adjusting for randomisation strata All analyses gave each cluster equal weight. A log transformation was applied to the risk/rate for each cluster, where necessary. For clusters with no events, one event was added to all clusters in order that the log transformation could be conducted. The mean and standard deviation of these log risks/rates were used to obtain the geometric mean and associated 95% confidence interval (CI) for each arm of the study. The risk/rate ratio was estimated using linear regression of the log risks/rates on stratum and arm. Prior to randomisation, clusters were grouped into four strata, based on province (A, B, C and D). For the analysis three strata (A, C, and B and D combined) were included in the statistical analysis, as planned at the time of randomisation. B and D were similar with respect to urban/rural status. An approximate standard error for the log (risk ratio) based on geometric means of cluster risks between arms was obtained based on the residual mean square from a two-way analysis of variance of the cluster log prevalence/rate on stratum, study arm and the interaction between stratum and study arm. The 95% CI was calculated from this standard error, using a t-statistic with 14 degrees of freedom. Fully adjusted analysis controlling for randomisation strata and individual-level baseline factors Depending on the outcome to be analysed, Poisson/ logistic regression was used to adjust for confounders at the individual level adopting a two-stage approach(1). In stage 1 the regression model included terms for the adjustment factors and strata, but not study arm. For each cluster the fitted model was used to obtain the ratio of observed to expected (O/E) events, and a log transformation applied to this ratio, where appropriate. In stage 2 linear regression of the log(o/e) on stratum and arm was used to estimate the risk/rate ratio. The variance for the ratio of mean O/E was calculated from the residual mean square from an ANOVA of log(o/e) on stratum, arm and the interaction between stratum and arm. The 95% CI was calculated from this variance, using a t- statistic with 14 degrees of freedom. Analysis of risk factors for death within six months from enrolment A risk factor analysis using logistic regression was conducted to identify individual-level factors, including index specimen result, associated with six-month mortality risk. As the number of outcomes was limited (193 deaths among 4411 participants), controlling for cluster using a fixed-effect in the regression model was not possible. Instead all analyses were adjusted for province. A priori, sex and age group were included in the fullyadjusted model. 1. Hayes RJ, Moulton LH. Cluster randomised trials: Chapman & Hall;
4 Supplementary Table 1: six-month mortality risk by cluster (n=4656) Province Cluster code Deaths n % Microscopy A % A % A % A % B % D % C % C % C % C % Overall % Mean of cluster risks 5.0% Xpert A % A % A % A % B % D % C % C % C % C % Overall % Mean of cluster risks 3.9% 3
5 Supplementary Figure 1: South African algorithm for the investigation of tuberculosis using Xpert MTB/RIF 4
6 Supplementary Figure 2a: South African algorithm for tuberculosis diagnosis in a new case using smear microscopy and culture No previous TB or less than 4 weeks of TB treatment Send 2 sputum specimens for smear microscopy: 1 st spot specimen taken at the health facility under supervision 2 nd early morning specimen HIV- negative or HIV status unknown HIV positive Provide antibiotics. Send 3 rd specimen for smear and culture. If no improvement: Send 3 rd specimen for sputum smear and culture Do chest x-ray. Do chest x-ray. Provide antibiotics. TB on chest x-ray and No TB on chest x-ray TB on chest x-ray and No TB on chest x-ray HCW decision to treat on clinical grounds HCW decision to treat on clinical grounds Aim to provide full course of treatment. Review clinical picture and progress when culture result available for smear negative cases. Aim to provide full course of treatment. Review clinical picture and progress when culture and drug sensitivity available for smear negative cases. 5
7 Supplementary Figure 2b: South African algorithm for investigation of tuberculosis among persons at high risk of or previous treated for tuberculosis using smear microscopy, culture and drug sensitivity testing Previous TB (4 or more weeks of TB treatment) and high risk TB suspect (MDR contact, health care personnel, prisoner) Send 2 sputum specimens: 1 st spot specimen taken at the health facility for sputum smear microscopy 2 nd early morning specimen for sputum smear microscopy, culture and drug susceptibility testing (DST) HIV-negative or HIV status unknown HIV positive Provide antibiotics. Send 3 rd specimen for smear. If no improvement, send 3 rd specimen for sputum smear and do chest x-ray. Review drug sensitivity Do chest x-ray. Provide antibiotics TB on Chest x-ray and No TB on Chest x-ray TB on Chest x-ray and No TB on Chest x-ray HCW decision to treat on clinical grounds HCW decision to treat on clinical grounds Aim to provide full course of treatment. Review clinical picture and progress when culture available for smear negative cases. Review DST. Aim to provide full course of treatment. Review clinical picture and progress when culture available for smear negative. 6
HIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationPilot Summary Report Revisiting the cost-effectiveness of Xpert MTB/RIF: lessons learned from South Africa
Pilot Summary Report Revisiting the cost-effectiveness of Xpert MTB/RIF: lessons learned from South Africa Background In 2014, 1.5 million people died from tuberculosis (TB), 25% of whom had HIV, and 13%
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationDownloaded from:
Churchyard, GJ; Stevens, WS; Mametja, LD; McCarthy, KM; Chihota, V; Nicol, MP; Erasmus, LK; Ndjeka, NO; Mvusi, L; Vassall, A; Sinanovic, E; Cox, HS; Dye, C; Grant, AD; Fielding, KL (2015) Xpert MTB/RIF
More informationXpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection Results of Group Work DOTS expansion and enhancement Objective This group deals with the majority
More informationHeather Alexander, PhD
Xpert MTB/RIF: An Opportunity to Strengthen Laboratory Systems and Bridge the Laboratory-Program Gap Heather Alexander, PhD International Laboratory Branch Division of Global HIV/AIDS Centers for Disease
More informationDiagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm Kathryn Schnippel 1, Gesine Meyer-Rath 1,2, Lawrence Long 1, Wendy Stevens 3,4, Ian Sanne 1,2, and Sydney Rosen
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationTB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017
TB FIT Modelling 24th Annual PhilCAT Convention Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017 TB-FIT - Objectives 1. Develop a computer model of patient pathways for diagnosis
More informationNational Xpert MTB/RIF Programme
National Xpert MTB/RIF Programme 1. Background to Project This project was initiated at the request of the Honorable Minister of Health, Dr Aaron Motsoaledi, in early 2011, following the World Health Organization
More informationClinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers
More informationThe 1 st National TB Prevalence Survey Nigeria 2012
The 1 st National TB Prevalence Survey Nigeria 2012 Preliminary/Final Results 29 th April 2013 Dr. Joshua Obasanya NTP Manager/ PI National TB Prevalence Survey Background Indicator (2011) Population size
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More informationThe first National TB Prevalence Survey Rwanda 2012
The first National TB Prevalence Survey Rwanda 2012 Preliminary Results 29 th April 2013 Patrick Migambi Rwanda Biomedical Centre (RBC) Background Indicator (2011) Population size(census 2012) 10,537,222
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More information: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
More informationMinistry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)
Ministry of Health National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015) Contents Executive summary... 2 Background... 3 National Tuberculosis Program Overview... 3
More informationTB prevention studies in PLHIV: recent updates and what can they tell us for the future?
TB prevention studies in PLHIV: recent updates and what can they tell us for the future? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University TB/HIV Working
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationVirtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine
Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine 3rd sector OR and developing countries 27th March 2013, London School of Economics
More informationProgress Report March 2016
Progress Report March 2016 Table of Contents Background to project 3 Assays performed to date 3 Correctional Services 5 Peri-Mining 6 Rif Concordance 7 Training: Laboratory and Clinical 7 Challenges identified
More informationProtocol of National TB Prevalence Survey in Cambodia
Training workshop for consultants of TB prevalence surveys Protocol of National TB Prevalence Survey in Cambodia 26 February 2011 Phnom Penh, Cambodia Norio Yamada, RIT/JATA Training workshop for consultants
More informationOngoing Research on LTBI and Research priorities in India
Ongoing Research on LTBI and Research priorities in India Dr. C.Padmapriyadarsini, MD, MS ICMR-National Institute for Research in Tuberculosis Chennai, India Technical Consultation Meeting on Programmatic
More informationThe National TB Prevalence Survey Pakistan
The National TB Prevalence Survey Pakistan 2010-11 Preliminary Results 29 th April 2013 Dr Ejaz Qadeer NTP Manager Principal Investigator Background Indicator (2012) Population size GNI per capita (Atlas
More informationHealth Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)
Health Care Worker Training on Roll Out New TB Diagnostic Test Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien) Overview Specimen Collection Investigations to request Sorting & registering
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationWhat Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ
What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key
More informationCULTURE OR PCR WHAT IS
CULTURE OR PCR WHAT IS BEST FOR AFRICA? Peter R Mason BRTI TB IN AFRICA GLOBAL 9 MILLION NEW CASES/YR 1.5 MILLION TB DEATHS AFRICA 95% TB DEATHS IN LMIC 9/22 HIGH BURDEN COUNTRIES IN AFRICA STRONG LINK
More informationBackground paper number 7
Background paper number 7 Lessons learnt and policy implications from recently completed TB disease prevalence surveys and their interpretation - Vietnam Binh Hoa Nguyen Prevalence survey in Vietnam 2006-2007
More informationCost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis
Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis among people living with HIV Somya Gupta, Taiwo Abimbola, Anand Date, Amitabh B. Suthar, Rod Bennett, Nalinee Sangrujee, Reuben
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationAnalysis of TB prevalence surveys
Workshop and training course on TB prevalence surveys with a focus on field operations Analysis of TB prevalence surveys Day 8 Thursday, 4 August 2011 Phnom Penh Babis Sismanidis with acknowledgements
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationNATIONAL TUBERCULOSIS PREVALENCE SURVEY 2016
NATIONAL TUBERCULOSIS PREVALENCE SURVEY 2016 Department of Health/National TB Control Program Philippine Council for Health Research and Development Foundation for the Advancement of Clinical Epidemiology,
More informationAssessing spatial heterogeneity of MDR-TB in a high burden country
Assessing spatial heterogeneity of MDR-TB in a high burden country Appendix Helen E. Jenkins 1,2*, Valeriu Plesca 3, Anisoara Ciobanu 3, Valeriu Crudu 4, Irina Galusca 3, Viorel Soltan 4, Aliona Serbulenco
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationUGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
MINISTRY OF HEALTH UGANDA TIOL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME Revised Strategic Plan 2015/16-2019/20 Monitoring and Evaluation Plan Narrative of the Operational, Budget and Technical Assistance
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationNational tuberculosis prevalence surveys in Asia, : an overview of results and lessons learned
Tropical Medicine and International Health doi:10.1111/tmi.12534 volume 20 no 9 pp 1128 1145 september 2015 National tuberculosis prevalence surveys in Asia, 1990 2012: an overview of results and lessons
More informationComparative performance of emerging rapid diagnostics in HIV-infected individuals
Comparative performance of emerging rapid diagnostics in HIV-infected individuals Maunank Shah M.D. Johns Hopkins University Clinical Diagnostics Research Consortium Background Emerging diagnostics may
More informationRapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.
Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients. Item Type Thesis Authors Patel, Ravikumar Publisher The University of Arizona. Rights Copyright
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationEffectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine
More informationDr Richard Christopher,(Pediatrician) Ministry of Health and Social Welfare NTLP- TANZANIA Tanzania. Childhood TB Roadmap Paris 0ctober 29
Dr Richard Christopher,(Pediatrician) Ministry of Health and Social Welfare NTLP- TANZANIA Tanzania Childhood TB Roadmap Paris 0ctober 29 Status of childhood TB in Tanzania Child TB linkages with National
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationDr Clare van Halsema
19 th Annual Conference of the British HIV Association (BHIVA) Dr Clare van Halsema North Manchester General Hospital 16-19 April 2013, Manchester Central Convention Complex The effect of antiretroviral
More informationOverview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions
202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationPrevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials
Prevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials Videlis Nduba 1,2, Peter Onyango 1, Anja Van t Hoog 1,3, Anthony Hawkridge
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
More informationChallenges in Capacity in SA for diagnosing DR-TB
National Tuberculosis Reference Laboratory Challenges in Capacity in SA for diagnosing DR-TB March 2010 Gerrit Coetzee Rapid response to XDR-TB WHO Global Task Force on XDR-TB, October 2006 Accelerate
More informationQian Gao Fudan University
Qian Gao Fudan University Outline Background & Objectives Genotyping methods Establish the epidemiological field sites Preliminary results of Molecular epidemiology of TB in China Molecular epidemiology
More informationSoedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
More informationIntroduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationModern TB Diagnostic Services: Optimizing the Old with the New
Modern TB Diagnostic Services: Optimizing the Old with the New 6 th Global Laboratory Initiative (GLI) Partners Meeting incorporating Global consultation of the TB SRL Network Global Forum of Xpert MTB/RIF
More informationTB Program and Epidemic aka B2B
TB Program and Epidemic aka B2B Nulda Beyers On behalf of DTTC BOD Workshop 30 September2013 Trend in tuberculosis incidence, selected countries in Africa 1400 1200 Rate per 100,000 1000 800 600 400 200
More informationSAME-DAY-DIAGNOSIS OF TUBERCULOSIS BY MICROSCOPY - POLICY STATEMENT -
SAME-DAY-DIAGNOSIS OF TUBERCULOSIS BY MICROSCOPY - POLICY STATEMENT - March 2010 EXECUTIVE SUMMARY Direct sputum smear microscopy is the most widely used test for the diagnosis of pulmonary tuberculosis
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationImplementation of Xpert MTB/RIF : Experience of Republic of Moldova
Implementation of Xpert MTB/RIF : Experience of Republic of Moldova Domente Liliana Institute of Phthisiopneumology Chiril Draganiuc Antalia, Turkey December 10-13, 2013 TB Epidemic Breakdown Indicator
More informationThe innovation gaps and challenges for MDR-TB. Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board
The innovation gaps and challenges for the diagnostic and treatment of TB and MDR-TB Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board Diagnosis Overview of
More informationComparative evaluation of diagnostic performance of Xpert between paired IS and GW in children <3.5 years in Cape Town, SA
Comparative evaluation of diagnostic performance of Xpert between paired IS and GW in children
More informationApplication of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes
Application of the Onion model to assess the extent of missing tuberculosis cases by the National Programmes Dr Amal Bassili Stop TB unit, WHO, Regional Office for the Eastern Mediterranean Surveillance
More informationPlanning for country transition to Xpert MTB/RIF Ultra Cartridges
Planning for country transition to Xpert MTB/RIF Ultra Cartridges Planning for country transition to Xpert MTB/RIF Ultra cartridges April 2017 Contents Acknowledgements About this guide Target audience
More informationRole of RNTCP in the management MDR-TB
Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A
More informationBackground: XpertMTB/RIF
Xpert MTB/RIF vs microscopy as the first line TB test in South Africa: mortality, yield,initial loss to follow up and proportion treated. The XTEND study GJ Churchyard On behalf of the XTEND team (Xpert
More informationGuidelines for TB contact tracing in Pacific Island countries and territories
Guidelines for TB contact tracing in Pacific Island countries and territories Background Tuberculosis (TB) continues to be a public health issue of major significance around the world. The World Health
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Dorman S E, Schumacher S G, Alland D, et al.
More informationPredictive statistical modelling approach to estimating TB burden. Sandra Alba, Ente Rood, Masja Straetemans and Mirjam Bakker
Predictive statistical modelling approach to estimating TB burden Sandra Alba, Ente Rood, Masja Straetemans and Mirjam Bakker Overall aim, interim results Overall aim of predictive models: 1. To enable
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationOutline. Milestone of survey in Myanmar Objectives Method Results Discussion Limitation Programme implications
MHAA Outline Milestone of survey in Myanmar Objectives Method Results Discussion Limitation Programme implications 1972 National TT survey 1994 National Sputum smear positive TB prevalence survey Protocol
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationC Reactive Protein for TB Screening. Christina Yoon, MD, MAS Advanced TB Diagnostics Research Course June 24, 2016
C Reactive Protein for TB Screening Adithya Cattamanchi MD MAS Adithya Cattamanchi, MD, MAS Christina Yoon, MD, MAS Advanced TB Diagnostics Research Course June 24, 2016 Recommendations 1-3 Should be done:
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationMULTI-COUNTRY WESTERN PACIFIC PROGRAMME. Empowered lives. Resilient nations. PROGRAMME BRIEF OCTOBER 2017
MULTI-COUNTRY WESTERN PACIFIC PROGRAMME Empowered lives. Resilient nations. PROGRAMME BRIEF OCTOBER 2017 SUPPORTING NATIONAL PROGRAMMES The Multi-Country Western Pacific Programme seeks to improve coverage
More informationLatest developments in WHO estimates of TB disease burden
Latest developments in WHO estimates of TB disease burden WHO Global Task Force on TB Impact Measurement meeting Glion, 1-4 May 2018 Philippe Glaziou, Katherine Floyd 1 Contents Introduction 3 1. Recommendations
More informationIntensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite
Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.
More informationClinical use of a TB Diagnostic using LAM Detection in Urine. Robin Wood, IDM, University of Cape Town
Clinical use of a TB Diagnostic using LAM Detection in Urine Robin Wood, IDM, University of Cape Town Declaration of Interests Statement Robin Wood, FCP (SA), D.Sc.(Med), FRS (SA). Emeritus Professor of
More informationProgress Report July 2014
Progress Report July 2014 Table of Contents Background to project 3 Assays performed to date 5 Rif Concordance 8 Errors 8 Monthly uptake since implementation started 10 Specific GeneXpert Site Progress
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationFinding the missing TB cases
Finding the missing TB cases Optimizing strategies to enhance case detection in high HIV burden settings Dr Malgosia Grzemska Global TB Programme, WHO/HQ, Geneva SWITZERLAND Child and Adolescent TB Working
More informationTuberculosis in England 2018 report (presenting data to end of 2017) Tables and figures slide set
Tuberculosis in England 2018 report (presenting data to end of 2017) Tables and figures slide set Number of TB notifications and rates, England, 1971-2017 2 Tuberculosis in England: 2018 report, Office
More informationThe Health Economics and Epidemiology Research Office (HE 2 RO): An overview of research methods and results
The Health Economics and Epidemiology Research Office ( ): An overview of research methods and results Gesine Meyer-Rath Lawrence Long Kathryn Schnippel Introducing Collaboration between Wits and BU Established
More informationPhase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1
Phase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1 Preliminary results from two phase III drug-resistant TB (DR-TB) clinical trials were presented
More information- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011
- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011 This document provides an update on the global roll-out of Xpert MTB/RIF, the WHO-endorsed test for the rapid and simultaneous detection
More informationOriginal Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
Int J Clin Exp Pathol 2017;10(4):4847-4851 www.ijcep.com /ISSN:1936-2625/IJCEP0045802 Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
More informationAdverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease
Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease J. Sukanya 05.Jul.2012 Outline Background Methods Results Discussion Appraisal Background Common outcomes in hospitalized
More informationBackground paper number 5
Background paper number 5 Assessing the quality and coverage of surveillance data in the UK: how is it done and how can HPA help to develop the Task Force framework for assessment of surveillance data,
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationRam Sharan Gopali (MPH) Executive Director
Ram Sharan Gopali (MPH) Executive Director Basic Facts of Nepal Nepal is a landlocked country located in the WHO Asian region at the edge of the Himalaya between India and the Peoples Republic of China
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationSame-day diagnosis of tuberculosis by microscopy. Policy statement
Same-day diagnosis of tuberculosis by microscopy Policy statement March 2010 Contents Abbreviations Executive summary 1. Background 2. Evidence for policy formulation 2.1 Synthesis of evidence 2.2 Management
More informationSystematic screening for active TB operational manual and tool to help prioritization
Systematic screening for active TB operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme, 1 Strong recommendations = Should be screened in all settings 1.
More informationSURVEY FINDINGS April 28, 2017
SURVEY FINDINGS April 28, 2017 Brenda Mungai Centre for Health Solutions-Kenya, TB ARC Outline Background Survey Rationale Methods Key Findings Conclusions Call to Action KENYA TUBERCULOSIS PREVALENCE
More informationProcurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
More information